Shivani Srivastava, M.D.
About Shivani Srivastava, M.D.
Shivani Srivastava, M.D., is the Vice President Development Program Lead Cell Therapy at Bristol Myers Squibb, with extensive experience in oncology clinical development and a strong background in hematology and oncology.
Title at Bristol Myers Squibb
Currently, Shivani Srivastava, M.D., holds the position of Vice President Development Program Lead Cell Therapy at Bristol Myers Squibb. In this role, she oversees the strategic planning and execution of cell therapy development programs. Her focus is on driving innovation and advancing therapeutic options within the realm of cell therapy for oncology patients.
Career at Bristol Myers Squibb
Shivani Srivastava, M.D., has held multiple roles at Bristol Myers Squibb. From 2019 to 2021, she served as the Executive Director, Clinical Team Leader, Oncology Clinical Development. Before that, she was the Program Lead for Oncology Clinical Development (2017-2019) and for Oncology Early Clinical Development (2016-2017). She began her tenure at the company as a Medical Director from 2013 to 2016. Throughout these roles, she has contributed significantly to both early and late-stage clinical development programs.
Experience at Indiana University School of Medicine
Shivani Srivastava, M.D., worked at Indiana University School of Medicine as Director of the Cellular Therapy Laboratory from 2012 to 2013. Additionally, she was an Assistant Professor of Medicine from 2007 to 2013. Her responsibilities included advancing cellular therapy research and mentoring junior researchers, contributing to the institution's academic and clinical environments.
Educational Background in Medicine
Shivani Srivastava, M.D., obtained her MBBS from Kasturba Medical College, Manipal (1994-2001). She pursued the Internal Medicine Residency Program at the State University of New York Upstate Medical University from 2001 to 2003 and at Jefferson Health from 2003 to 2004. She completed a Hematology-Oncology Fellowship at the National Institutes of Health from 2004 to 2007, establishing a strong foundation in hematology and oncology.
Leadership in Oncology Clinical Development
With over a decade of experience in oncology clinical development, specifically in cell therapy, Shivani Srivastava, M.D., has been pivotal in the development and approval of multiple oncology therapies at Bristol-Myers Squibb. She led the development of Breyanzi, a CAR T cell therapy for the treatment of certain types of lymphoma. Her leadership roles within the company reflect a progressive career trajectory, and she is known for mentoring junior researchers and clinicians.